Search

Your search keyword '"Brian H, Kushner"' showing total 141 results

Search Constraints

Start Over You searched for: Author "Brian H, Kushner" Remove constraint Author: "Brian H, Kushner" Topic medicine.medical_specialty Remove constraint Topic: medicine.medical_specialty
141 results on '"Brian H, Kushner"'

Search Results

1. Re-thinking transplant for neuroblastoma

2. Mandibular metastases in neuroblastoma: Outcomes and dental sequelae

3. Treatment and revaccination of children with paraneoplastic opsoclonus‐myoclonus‐ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience

4. Short Hypofractionated Radiation Therapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities

5. 963MO Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201

6. MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy

7. Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma

8. Assessment of pulmonary outcomes, exercise capacity, and longitudinal changes in lung function in pediatric survivors of high-risk neuroblastoma

9. Efficacy of naxitamab in patients with refractory/relapse (R/R) high-risk neuroblastoma (HR-NB) by bone/bone marrow (BM) evaluation, potential sites of residual disease

10. Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma

11. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma

12. Enigmatic entities: opsoclonus myoclonus ataxia syndrome linked to neuroblastoma

13. 74P Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)

14. 75P Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)

15. Long-term Survivors Receive Multimodality Treatment of Second Central Nervous System Relapse in Pediatric Patients with Neuroblastoma

16. Abstract LB-092: Survival impact of anti-GD2 antibody response - A phase II ganglioside vaccine trial in relapsed neuroblastoma

17. Reduced-dose Radiation Therapy to the Primary Site is Effective for High-risk Neuroblastoma: Results from a Prospective Trial

18. Bevacizumab-Associated Bowel Microperforation in a Patient with Neuroblastoma

19. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study

20. Desmoplastic small round cell tumor 20 years after its discovery

21. Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

22. Key role for myeloid cells: Phase II results of anti-GD2antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma

23. Striking dichotomy in outcome ofMYCN-amplified neuroblastoma in the contemporary era

24. Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission

25. Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study

26. Short-Interval Retreatment With Stereotactic Body Radiotherapy (SBRT) for Pediatric Neuroblastoma Resulting in Severe Myositis

27. Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD23F8 monoclonal antibody

28. Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy

29. Reduced Toxicity With Intensity Modulated Radiation Therapy (IMRT) for Desmoplastic Small Round Cell Tumor (DSRCT): An Update on the Whole Abdominopelvic Radiation Therapy (WAP-RT) Experience

30. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study

31. Chemoimmunotherapy for high-risk neuroblastoma

32. High-dose cyclophosphamide–irinotecan–vincristine for primary refractory neuroblastoma

33. Humanized 3F8 Anti-GD2Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma

34. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma

35. Hypothyroidism after 131 I-monoclonal antibody treatment of neuroblastoma

36. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma

37. Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass

38. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin

39. Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma

40. Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system

41. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma

42. Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma

43. Long-term complications in survivors of advanced stage neuroblastoma

44. The impact of gross total resection on local control and survival in high-risk neuroblastoma

45. Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing’s Family of Tumors in Children and Young Adults

46. Oral Topotecan for Refractory and Relapsed Neuroblastoma: A Retrospective Analysis

47. Curability of Recurrent Disseminated Disease After Surgery Alone for Local-Regional Neuroblastoma Using Intensive Chemotherapy and Anti-GD2 Immunotherapy

48. Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor

49. Chronic neuroblastoma

50. SCDT-38. SAFETY AND EFFICACY OF INTRAVENTRICULAR 131I-LABELED MONOCLONAL ANTIBODY 8H9 TARGETING THE SURFACE GLYCOPROTEIN B7-H3 IN PATIENTS WITH CNS/LM DISEASE

Catalog

Books, media, physical & digital resources